Skip to main content

Merendino Lauren's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Aug 19, 2025

Accession no.
0001415889-25-022376
Filed
Aug 19, 2025
Trade date
Aug 15-18, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $25.5K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Merendino LaurenCIK 0001855298Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 15, 2025Common StockMOption exerciseAcquired+3,162––38,323Direct
Aug 15, 2025Common StockMOption exerciseAcquired+3,687––42,010Direct
Aug 15, 2025Common StockMOption exerciseAcquired+3,687––45,697Direct
Aug 18, 2025Common StockSSaleDisposed−3,766$6.77−$25,495.8241,931Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 15, 2025Common StockMOption exerciseDisposed−3,162$0.00$025,302Direct
Aug 15, 2025Common StockMOption exerciseDisposed−3,687$0.00$033,191Direct
Aug 15, 2025Common StockMOption exerciseDisposed−3,687$0.00$047,939Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)